Pfizer Studying Coadministration of Covid-19 Booster, Pneumococcal Shots
May 24 2021 - 7:21AM
Dow Jones News
By Matt Grossman
Pfizer Inc. has enrolled the first subjects in a study testing
the coadministration of the company's Covid-19 booster shot along
with Pfizer's 20-valent pneumococcal conjugate vaccine.
The study, which includes 600 people age 65 or older, will study
the safety of giving the two shots together. Some people in the
study will get both shots, while others will get just one of the
two vaccines plus a placebo.
The trial's subjects were recruited from the cohort that
participated in Pfizer's Phase 3 trial for its Covid-19 vaccine
last year.
Pfizer developed its Covid-19 vaccine with BioNTech SE.
Write to Matt Grossman at matt.grossman@wsj.com
(END) Dow Jones Newswires
May 24, 2021 07:07 ET (11:07 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
BioNTech (NASDAQ:BNTX)
Historical Stock Chart
From Mar 2024 to Apr 2024
BioNTech (NASDAQ:BNTX)
Historical Stock Chart
From Apr 2023 to Apr 2024